At Alnylam, we believe that the discovery and development of RNAi therapeutics is only the first step – it is our responsibility to be as innovative delivering new medicines for patients as we are in the lab.

Our Patient Access Philosophy guides our approach to access, affordability, and outcomes as they relate to our therapies, and the therapeutic areas we serve.

Every year, we measure and report out on our progress in these areas. Following is data representing 2022 progress.

**Above All, We Put Patients First**

We recognize that access and affordability mean more than insurance coverage and reimbursement. We commit to listen and learn from patients, caregivers, healthcare providers, payers, and regulatory bodies to develop and advocate for sustainable solutions that improve access and outcomes. We strive to provide resources that are relevant to the patient and their treatment team, and help make decisions that are best for them.

We believe proactive steps for better access today will advance innovation that will enable us to help even more people in the future.

### 1,000+
U.S. patients enrolled in Alnylam Assist™

### 4.8
on a 5.0 scale average U.S. Alnylam Assist patient satisfaction score for all Alnylam therapeutics

### ZERO
U.S. zero cost-share for ONPATTRO®, GIVLAARI®, OXLUMO® or AMVUTTRA® in U.S.

- ONPATTRO: 69% have zero cost-share in U.S.
- AMVUTTRA: 69% have zero cost-share in U.S.
- GIVLAARI: 85% have zero cost-share in U.S.
- OXLUMO: 93% have zero cost-share in U.S.

### 350+
U.S. patients enrolled in commercial copay program

### 700+
patients received Alnylam therapeutics under compassionate use worldwide

### 3,775+
patients on Alnylam commercial therapy worldwide

### 40+
markets where patients have received access to Alnylam therapies

### 92%-99%
of U.S. residents who have confirmed access to Alnylam therapies across commercial, Medicare, Medicaid, and other government payer categories

- ONPATTRO: 99.6% of monitored lives have confirmed access
- AMVUTTRA: 92% of all monitored lives have confirmed access
- GIVLAARI: 99.6% of monitored lives have confirmed access
- OXLUMO: 99% of monitored lives have confirmed access

### We Provide Value that Transcends Borders

We commit to responsible, evidence-based pricing of our products to reflect the value delivered to patients, caregivers and society. We remain committed to growth through continuous innovation, not arbitrary price increases, and expanding our geographic reach to create sustainable access pathways for patients around the world.

We view patient access as a responsibility that requires innovative, sustainable solutions developed in collaboration with all those involved in the delivery of care.

### 60+
markets where patients have direct or distributor access to our medicines

### 60+
value-based agreements signed with U.S. payers across products

**Continued on back page**

© 2023 Alnylam Pharmaceuticals, Inc. ALNYPAPR 07/23
We Are Proactive and Accountable

We recognize that no single solution can meet all challenges, and the importance of acting with medical and scientific excellence, and integrity. We advocate for policies that promote innovation and value communication, so that eligible patients can access our medicines. We track and report our efforts to help patients access therapy.

We continue to innovate, acting with urgency to minimize the time it takes to get approved therapies to patients.

490+ U.S. patient education events hosted by Alnylam

90 patient advocacy organizations engaged in Alnylam’s network globally

13,000+ people participated in Alnylam-sponsored clinical trials in Europe

77,000+ people genotyped through Alnylam Act™ or GeneAct™ since the program began

Definitions of Key Alnylam Programs Related to Access and Affordability

Expanding Patient Access Programs

Through various patient access programs, we provide patients access to diagnostic resources and genetic testing and we remove barriers for patients to gain access to our commercially available therapeutics. In addition, we enable access to our investigational drugs for treatment outside clinical trials when no comparable or satisfactory alternative therapy options are available. Our key programs include:

• **Alnylam Act** provides an option for no-charge, third-party genetic testing and counseling for people with a family history or suspected diagnosis of certain genetic diseases.

• **Alnylam** has partnered with genetic testing experts around the world to provide programs including GeneAct, GENILAM™, DetecTTA, TRAMmoniTTR, and others to provide patient and physician education and spread knowledge about the resources available to help those at risk, or drive earlier, more accurate diagnosis.

• **Alnylam Assist™** offers personalized services helping patients understand insurance coverage for therapy, informing them of options and eligibility for financial support, providing materials to start conversations with physicians and family members, and sharing information on patient advocacy organizations and other resources.

• **Alnylam’s Compassionate Use Policy** outlines when we will consider providing treatment for an individual patient outside a clinical trial. We evaluate all requests in a fair and equitable manner.

For more information on Alnylam’s approach to access and affordability, please visit [alnylam.com/access](http://alnylam.com/access)